231 related articles for article (PubMed ID: 26240252)
21. Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remain.
Chambers JD; May KE; Neumann PJ
Health Aff (Millwood); 2013 Jun; 32(6):1109-15. PubMed ID: 23733986
[TBL] [Abstract][Full Text] [Related]
22. Looking at CER from Medicare's perspective.
Mohr P
J Manag Care Pharm; 2012 May; 18(4 Suppl A):S5-8. PubMed ID: 22578211
[TBL] [Abstract][Full Text] [Related]
23. Health services utilization in the U.S. population by health insurance coverage.
Garfinkel SA; Corder LS
Natl Med Care Util Expend Surv B; 1986 Dec; (13):1-38. PubMed ID: 10304187
[TBL] [Abstract][Full Text] [Related]
24. Considering changes to CMS's national coverage decision process: applying lessons learned from FDA as a regulator of access to healthcare technology.
Zalesky CD
Food Drug Law J; 2002; 57(1):73-93. PubMed ID: 12118482
[No Abstract] [Full Text] [Related]
25. The impact of Medicare coverage policies on health care utilization.
Foote SB; Virnig BA; Town RJ; Hartman L
Health Serv Res; 2008 Aug; 43(4):1285-301. PubMed ID: 18479413
[TBL] [Abstract][Full Text] [Related]
26. From medical invention to clinical practice: the reimbursement challenge facing new device procedures and technology--part 2: coverage.
Raab GG; Parr DH
J Am Coll Radiol; 2006 Oct; 3(10):772-7. PubMed ID: 17412167
[TBL] [Abstract][Full Text] [Related]
27. Proposal for a national coverage determination for the treatment of varicose veins and venous disease due to disparate Centers for Medicare and Medicaid Services local coverage determination policies.
Welch HJ; Kabnick L; Vasquez MA; Monahan DL; Lurie F; Jacobowitz G
J Vasc Surg Venous Lymphat Disord; 2017 May; 5(3):453-459. PubMed ID: 28411715
[TBL] [Abstract][Full Text] [Related]
28. Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019.
Douglas MP; Gray SW; Phillips KA
J Natl Compr Canc Netw; 2020 Jul; 18(7):866-872. PubMed ID: 32634780
[TBL] [Abstract][Full Text] [Related]
29. HCFA updates PPS medical review instructions.
Natl Rep Subacute Care; 2000 Mar; 8(5):1-3. PubMed ID: 10788004
[No Abstract] [Full Text] [Related]
30. Supplemental health insurance coverage among aged Medicare beneficiaries.
Garfinkel SA; Corder LS
Natl Med Care Util Expend Surv B; 1985 Aug; (5):1-37. PubMed ID: 10304189
[TBL] [Abstract][Full Text] [Related]
31. Rules for medical markets: the impact of medicare contractors on coverage policies.
Foote SB; Wholey D; Halpern R
Health Serv Res; 2006 Jun; 41(3 Pt 1):721-42. PubMed ID: 16704509
[TBL] [Abstract][Full Text] [Related]
32. Opacity and cost effectiveness analysis in Medicare coverage decisions: health policy encounters administrative law.
Kolber MS
Food Drug Law J; 2009; 64(3):515-30. PubMed ID: 19999645
[TBL] [Abstract][Full Text] [Related]
33. Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019.
Trosman JR; Douglas MP; Liang SY; Weldon CB; Kurian AW; Kelley RK; Phillips KA
Value Health; 2020 May; 23(5):551-558. PubMed ID: 32389219
[TBL] [Abstract][Full Text] [Related]
34. Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment.
Douglas MP; Ragavan MV; Chen C; Kumar A; Gray SW; Blakely CM; Phillips KA
J Natl Compr Canc Netw; 2023 Jun; 21(6):609-616.e4. PubMed ID: 37308126
[TBL] [Abstract][Full Text] [Related]
35. Commentary: the impact of Medicare coverage policies on health care utilization.
Garber AM
Health Serv Res; 2008 Aug; 43(4):1302-7. PubMed ID: 18479412
[No Abstract] [Full Text] [Related]
36. Financial Conflicts of Interest in Public Comments on Medicare National Coverage Determinations of Medical Devices.
Lu A; Ji RZ; Ge AY; Ross JS; Ramachandran R; Redberg RF; Dhruva SS
JAMA; 2023 Sep; 330(11):1094-1096. PubMed ID: 37589985
[TBL] [Abstract][Full Text] [Related]
37. Private payers and cancer care: land of opportunity.
Klein I; Kolodziej M
J Oncol Pract; 2014 Jan; 10(1):15-9. PubMed ID: 24084888
[TBL] [Abstract][Full Text] [Related]
38. The review process used by US health care plans to evaluate new medical technology for coverage.
Steiner CA; Powe NR; Anderson GF; Das A
J Gen Intern Med; 1996 May; 11(5):294-302. PubMed ID: 8725978
[TBL] [Abstract][Full Text] [Related]
39. Business of Health: Business of Health Insurance.
Berry MD;
Issue Brief Health Policy Track Serv; 2015 Dec; ():1-87. PubMed ID: 27116765
[No Abstract] [Full Text] [Related]
40. Medicare beneficiaries less likely to experience cost- and access-related problems than adults with private coverage.
Davis K; Stremikis K; Doty MM; Zezza MA
Health Aff (Millwood); 2012 Aug; 31(8):1866-75. PubMed ID: 22813985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
